Vascular diseases

CES 2021 Mission for the human race, Pulxion's early detection technology is here to save lives

Thursday, January 14, 2021 - 8:04am

Pulxion's first product, PulStroke, is a novel fast-screening device for carotid artery stenosis, an early indicator of stroke.

Key Points: 
  • Pulxion's first product, PulStroke, is a novel fast-screening device for carotid artery stenosis, an early indicator of stroke.
  • Current clinical diagnosis procedures for early detection of carotid artery stenosis risk use Doppler ultrasound.
  • Therefore, patients without existing conditions are less willing to go through the assessment and thus lose the chance for early assessment and prevention.
  • These resources are accelerating the team's research and knowledge, and the company will be featured as a top-100 Taiwanese startup at CES 2021.

CES 2021 Mission for the Human Race, Pulxion’s Early Detection Technology Is Here to Save Lives.

Thursday, January 14, 2021 - 4:58am

Pulxions first product, PulStroke, is a novel fast-screening device for carotid artery stenosis, an early indicator of stroke.

Key Points: 
  • Pulxions first product, PulStroke, is a novel fast-screening device for carotid artery stenosis, an early indicator of stroke.
  • Current clinical diagnosis procedures for early detection of carotid artery stenosis risk use Doppler ultrasound.
  • Therefore, patients without existing conditions are less willing to go through the assessment and thus lose the chance for early assessment and prevention.
  • These resources are accelerating the teams research and knowledge, and the company will be featured as a top-100 Taiwanese startup at CES 2021.

Genuity Science Wins 2021 BIG Innovation Award for Novel Genome Sequencing Approach

Tuesday, January 12, 2021 - 7:11pm

BOSTON, Jan. 12, 2021 /PRNewswire/ -- Genuity Science , a genomics and data-sourcing, analytics and insights organization, today announced that it has been named a winner in the 2021 BIG Innovation Awards presented by the Business Intelligence Group.

Key Points: 
  • BOSTON, Jan. 12, 2021 /PRNewswire/ -- Genuity Science , a genomics and data-sourcing, analytics and insights organization, today announced that it has been named a winner in the 2021 BIG Innovation Awards presented by the Business Intelligence Group.
  • The BIG innovation Awards recognize those organizations and people who bring new ideas to life, and change the way we experience the world.
  • Genuity Science's AI technology sifted through a large amount of high-dimensional data without a starting hypothesis, allowing the teams to uncover novel causal connections at the single-cell level.
  • "We are honored to be recognized for our deep learning approach that helped, in part, discover the underlying cause of thoracic aortic aneurysms," said Tom Chittenden, PhD, DPhil, PStat, Chief Data Science Officer, Genuity Science.

Endospan Enrolls First Patient in the TRIOMPHE IDE Study

Tuesday, January 12, 2021 - 2:00pm

Endospan , a pioneer in off-the-shelf endovascular repair of aortic arch disease, announces the first implant of the NEXUS Aortic Arch Stent Graft System on a patient with a thoracic aortic aneurysm as part of the TRIOMPHE Study in Norfolk, Virginia, January 11, 2021.

Key Points: 
  • Endospan , a pioneer in off-the-shelf endovascular repair of aortic arch disease, announces the first implant of the NEXUS Aortic Arch Stent Graft System on a patient with a thoracic aortic aneurysm as part of the TRIOMPHE Study in Norfolk, Virginia, January 11, 2021.
  • The TRIOMPHE Study is a multi-arm, multi-center, non-randomized, prospective, clinical study to evaluate the safety and effectiveness of NEXUS in treating thoracic aortic lesions involving the aortic arch.
  • With the first patient enrolled in the TRIOMPHE IDE study, Endospan marks the next crucial milestone towards US approval for the NEXUS Aortic Arch Repair Stent Graft System, said Kevin Mayberry, CEO.
  • The NEXUS is specifically engineered for total endovascular arch repair to address the specific challenges of the aortic arch anatomy.

Lower-Profile Web Intrasaccular Aneurysm Treatment Device Receives FDA Approval

Tuesday, January 12, 2021 - 12:00pm

The WEB System is a unique, single-device treatment solution for wide neck bifurcation aneurysms in a new category of devices called intrasaccular flow disruptors.

Key Points: 
  • The WEB System is a unique, single-device treatment solution for wide neck bifurcation aneurysms in a new category of devices called intrasaccular flow disruptors.
  • When placed inside the aneurysm sac, the WEB device's proprietary microbraid technology bridges the aneurysm neck, disrupting blood flow, and creates a scaffold for long-lasting treatment.
  • "The excellent clinical results we can achieve with intrasaccular flow disruption technology has changed the way we approach the treatment of wide neck bifurcation aneurysms, and the WEB 17 System expands upon that.
  • When placed inside the aneurysm sac, the WEB device's proprietary microbraid technology bridges the aneurysm neck, disrupting blood flow, and creates a scaffold for long-lasting treatment.

United States $4.6 Billion Peripheral Vascular Devices and Accessories Market to 2027

Monday, January 11, 2021 - 4:00pm

The U.S. peripheral vascular devices and accessories market size is expected to reach USD 4.6 billion by 2027, expanding at a CAGR of 4.5%

Key Points: 
  • The U.S. peripheral vascular devices and accessories market size is expected to reach USD 4.6 billion by 2027, expanding at a CAGR of 4.5%
    Growing prevalence of venous diseases or Chronic Venous Insufficiency (CVI) is one of the key factors driving the growth of the market.
  • In addition, the peripheral stent market is majorly driven by a growing patient pool requiring the immediate stent placement, technological innovations in peripheral vascular interventions, and growing number of government initiatives.
  • Peripheral Devices & Accessories Market Variables, Trends, & Scope
    3.6 Number of Peripheral Vascular Procedures Performed, 2016 - 2027
    3.7 Average Cost of Peripheral Vascular Procedures, 2016 - 2027
    3.8 Average Selling Price (ASP) Analysis, By Product Type, 2016 - 2027
    Chapter 4 U.S.
  • Peripheral Devices & Accessories Market: Competitive Analysis
    4.1 Recent Developments & Impact Analysis, by Key Market Participants
    4.2 Company/Competition Categorization (Key Innovators, Market Leaders, Emerging Players)
    4.3 Key Company Market Share Analysis, 2019

Tactile Medical to Present at the ICR Conference 2021

Tuesday, January 5, 2021 - 12:30pm

MINNEAPOLIS, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. (Tactile Medical) (Nasdaq: TCMD), a medical technology company focused on developing medical devices for the treatment of chronic diseases at home, today announced that management will participate in a fireside chat at the ICR Conference 2021, which is being held virtually from January 11th-14th.

Key Points: 
  • MINNEAPOLIS, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. (Tactile Medical) (Nasdaq: TCMD), a medical technology company focused on developing medical devices for the treatment of chronic diseases at home, today announced that management will participate in a fireside chat at the ICR Conference 2021, which is being held virtually from January 11th-14th.
  • Tactile Medical is a leader in developing and marketing at-home therapy devices that treat chronic swelling conditions such as lymphedema and chronic venous insufficiency.
  • Tactile Medicals Mission is to help people suffering from chronic diseases live better and care for themselves at home.
  • Tactile Medical takes pride in the fact that our solutions help increase clinical efficacy, reduce overall healthcare costs and improve the quality of life for patients with chronic conditions.

Lui Franciosi Reviewing the Use of Sugar-Based Molecules as Potential Treatments for COVID-19

Tuesday, December 29, 2020 - 10:03pm

The clinically best-known GAG is heparin, which is an anticoagulant used for the treatment of thrombophlebitis, embolism, and thrombosis.

Key Points: 
  • The clinically best-known GAG is heparin, which is an anticoagulant used for the treatment of thrombophlebitis, embolism, and thrombosis.
  • I will be reviewing the existing scientific literature and searching out which GAG molecules could be pharmacologically active.
  • For more information about Lui Franciosi and his company Franciosi Consulting Ltd., please visit https://franciosiconsulting.com/ or his YouTube Channel https://www.youtube.com/channel/UC7PSoeH8yN-HuLg5xFi5Qxw/ .
  • Lui Franciosi founded Franciosi Consulting Ltd. in 2015 and is the president and CEO.

BIOMODEX Announces Presentation of Data at SFNR 2020 Highlighting Benefits of Patient-Specific Rehearsals in Complex Unruptured Intracranial Aneurysms

Thursday, December 17, 2020 - 9:07pm

Interventional neuroradiologists from France presented the results of a clinical study involving 20 patients at CHU Rennes with complex unruptured intracranial aneurysms.

Key Points: 
  • Interventional neuroradiologists from France presented the results of a clinical study involving 20 patients at CHU Rennes with complex unruptured intracranial aneurysms.
  • Using imaging scans, such as CTA and/or 3D rotational angiography, to visualize the inside of blood vessels and organs, Biomodex 3D-printed precise models of each individual patients' unruptured aneurysm.
  • Unlike silicone models, Biomodex models are created using biomechanical responsive advanced materials that simulate the characteristics and haptic feedback of the individual's anatomy.
  • Le Bras and Eugene presented at the 47 th Congress of the French Society of Neuroradiology SFNR on December 17, 2020.

Venclose to Participate in 2020 Piper Sandler Healthcare Conference

Monday, November 30, 2020 - 4:01pm

SAN JOSE, Calif., Nov. 30, 2020 /PRNewswire/ -- Venclose Inc., a privately-held medical device corporation focused on innovative advancements for the minimally invasive treatment of chronic venous insufficiency, a major underlying cause of varicose veins, today announced that Jerry Gibson, Venclose Chairman and CEO, will participate in the 32nd Annual Piper Sandler Healthcare Conference taking place virtually November 30 - December 3, 2020.

Key Points: 
  • SAN JOSE, Calif., Nov. 30, 2020 /PRNewswire/ -- Venclose Inc., a privately-held medical device corporation focused on innovative advancements for the minimally invasive treatment of chronic venous insufficiency, a major underlying cause of varicose veins, today announced that Jerry Gibson, Venclose Chairman and CEO, will participate in the 32nd Annual Piper Sandler Healthcare Conference taking place virtually November 30 - December 3, 2020.
  • "Venclose is honored to be one of the 40 private companies selected to participate in this year's conference," commented Mr. Gibson.
  • "We are pleased to share the company's commercial progress, a direct reflection of the quality of products in the Venclose portfolio and the hard work of its valued employees.
  • The Venclose Corporate Overview presentation can be viewed in the Newsroom section of the Venclose website: https://venclose.com/news/ .